Telitacicept is a dual-targeting agent that attaches to and blocks the effects of 2 key signaling proteins, B-lymphocyte ...

On June 16, 2025, RemeGen Co., Ltd. ('RemeGen', stock symbols: 688331.SH/09995.HK) announced that telitacicept (RC18; brand ...

Alexion to present seven abstracts, including four oral presentations, from its leading rare neurology portfolio at EAN 2025: Cambridge, UK Monday, June 23, 2025, 13:00 Hrs [IST] ...

The EC has approved argenx’s Vyvgart (efgartigimod alfa) 1000mg as a single agent for subcutaneous injection to treat CIDP.

Its growth is attributed to the anticipated launch of seven late-stage pipeline therapies. The myasthenia gravis (MG) market ...

The first patient enrolled in a planned international clinical trial has been treated at HonorHealth Research Institute with a new type of immune therapy for those with a rare muscle-weakness disease ...

Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company listed on the Nasdaq Composite Russell 1000 ...

Approval in Myasthenia gravis in key markets could eventually ... label study which found benefits for patients with anti-AchR antibody-positive gMG who had previously failed immunosuppressive ...

Myasthenia Gravis (MG) is a rare neurological disorder ... IM-101 is a humanized monoclonal antibody targeting complement C5 with high affinity. In the recently concluded Phase 1 clinical trial ...

Myasthenia gravis is a serious ... including the approval of Argenx' neonatal FC receptor (FcRn) antibody Vyvgart (efgartigimod alfa). The drug is currently available as an intravenous therapy ...

This regulatory approval is the second for VYVGART SC in Europe, which first received approval as an add-on to standard therpy for the treatment of adult patients with generalized myasthenia gravis ...